Stay updated on Nivolumab Plus Ipilimumab vs. Standard of Care Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab vs. Standard of Care Clinical Trial page.
Latest updates to the Nivolumab Plus Ipilimumab vs. Standard of Care Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedLocations section updated to add Lower Saxony as a trial site, expanding available locations. The page also removes the Lower Saxony Locations entry and the HHS Vulnerability Disclosure reference from the footer area.SummaryDifference0.2%
- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedThe page revision label changed from v3.2.0 to v3.3.2.SummaryDifference0.0%
- Check56 days agoChange DetectedThe government funding lapse notice in the Deletions section was removed; the page no longer displays that notice.SummaryDifference0.3%
- Check70 days agoChange DetectedNo significant content changes detected; the study details, locations, eligibility criteria, and endpoints remain the same, with only minor visual/layout adjustments visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check99 days agoChange DetectedThe page update introduces a funding-related operating status disclaimer and a new estimated last-update label, while removing the previous explicit “Last Update Posted” and the old revision tag.SummaryDifference2%
- Check106 days agoChange DetectedFinalized publication details and trial completion update with updated authorship and citation; provisional/older status dates removed in favor of published results.SummaryDifference4%
Stay in the know with updates to Nivolumab Plus Ipilimumab vs. Standard of Care Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab vs. Standard of Care Clinical Trial page.